Portfolio company
PetMedix
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
PetMedix develops species-specific monoclonal antibody therapeutics for companion animals to treat chronic and terminal diseases in dogs and cats.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ScoutBio
The company develops monoclonal antibodies and gene therapies for pets to treat chronic diseases.
adivo
This biotechnology company develops species-specific therapeutic monoclonal antibodies for companion animals, primarily targeting cancer and inflammatory diseases in dogs and cats.
Gallant Therapeutics
This company develops mesenchymal stromal cell therapies for veterinary professionals to treat inflammatory diseases and promote tissue repair in cats and dogs.
PETDX
This company develops liquid biopsy blood tests for the early detection of cancer in dogs for use by veterinary professionals.
DeepScan Diagnostics
This company develops cell-free DNA blood tests for veterinarians to detect cancer and monitor treatment response in dogs.
Animab
Animab develops oral monoclonal antibody products for livestock farmers to control gastrointestinal pathogens and improve animal health without using antibiotics.
Animol Discovery
This biopharmaceutical company develops small molecule medicines for companion and production animals using artificial intelligence and DNA-encoded library technologies.
Gallant
The company develops ready-to-use mesenchymal stromal cell therapies for veterinary professionals to treat inflammatory diseases and promote tissue repair in cats and dogs.
